Poxel to Gain Increased Royalties from Sumitomo Pharma for TWYMEEG Sales in Japan
Poxel Achieves Milestone with TWYMEEG® Sales in Japan, Secures Royalties and Sales-Based Payments Poxel, a clinical-stage biopharmaceutical company focused on innovative treatments for chronic serious diseases with metabolic pathophysiology—including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders—has announced a significant…